Compare · AYLA vs ZONE
AYLA vs ZONE
Side-by-side comparison of Ayala Pharmaceuticals Inc. (AYLA) and Zone Frontier Inc. (ZONE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AYLA and ZONE operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
- ZONE carries a market cap of $30.6M.
- ZONE has hit the wire 6 times in the past 4 weeks while AYLA has been quiet.
- AYLA has more recent analyst coverage (5 ratings vs 0 for ZONE).
- Company
- Ayala Pharmaceuticals Inc.
- Zone Frontier Inc.
- Price
- -
- -
- Market cap
- -
- $30.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- AMEX
- IPO
- 2020
- 2024
- News (4w)
- 0
- 6
- Recent ratings
- 5
- 0
Ayala Pharmaceuticals Inc.
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Zone Frontier Inc.
Zone Frontier Inc. (NYSE AMERICAN: ZONE) is helping to build the critical infrastructure that powers the AI economy. Through a growing pipeline of projects, the Company aims to help meet the increasing demand for compute capacity, power, and digital infrastructure required by the world's leading AI companies.
Latest AYLA
- SEC Form 3 filed by new insider Martell Bridget A
- SEC Form 3 filed by new insider Orbach Pini
- SEC Form 3 filed by new insider Golan Roy
- SEC Form 10-K filed by Ayala Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13G filed by Ayala Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)
- SEC Form 15-12G filed by Ayala Pharmaceuticals Inc.
- Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets
- SEC Form 4: Amoon Growth Fund Limited Partnership returned 2,991,473 shares to the company
Latest ZONE
- Amendment: SEC Form SCHEDULE 13G/A filed by Zone Frontier Inc.
- SEC Form SCHEDULE 13G filed by Zone Frontier Inc.
- SEC Form SCHEDULE 13G filed by Zone Frontier Inc.
- Zone Frontier Inc. Provides Shareholder Update on Minnesota Execution and Debt Financing Progress, Completed Strategic Transformation, Insider Share Purchases and Texas Project
- SEC Form 8-K filed by CleanCore Solutions Inc.
- Amendment: SEC Form 10-K/A filed by CleanCore Solutions Inc.
- Zone Frontier Inc. Announces 1-for-60 Reverse Stock Split
- Chief Executive Officer Hassen Tyler Lewis bought $55,150 worth of shares (500,000 units at $0.11) (SEC Form 4)
- Chief Executive Officer Hassen Tyler Lewis bought $85,200 worth of shares (750,000 units at $0.11) (SEC Form 4)
- SEC Form 8-K filed by CleanCore Solutions Inc.